Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Heres a quick comparison of the two: FDA Approval and Medical Uses Regulatory decisions play a big role in how medications are prescribed and who they are intended for
Understanding the relationship between these two can help you optimize your recovery, energy, and overall resilience
It means morning and evening applications serve different purposes
This application is intended for individuals without private insurance or access to government assistance programs like Medicare or Medicaid
